{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:17:38Z","timestamp":1790234258805,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>In Deutschland sind \u00c4rztinnen und \u00c4rzte, die Cannabisarzneimittel zulasten der gesetzlichen Krankenversicherung verschreiben, verpflichtet, an einer bis zum 31.03.2022 laufenden nichtinterventionellen Begleiterhebung zur Anwendung dieser Cannabisarzneimittel teilzunehmen.<\/jats:p><jats:p>Zum Zeitpunkt der Zwischenauswertung am 11.05.2020 lagen 10.010 vollst\u00e4ndige Datens\u00e4tze vor. Am h\u00e4ufigsten wurden Schmerzen (73\u202f%) als prim\u00e4r therapierte Symptomatik genannt, gefolgt von Spastik (10\u202f%) sowie Anorexie\/Wasting (6\u202f%). Verordnet wurden in 65\u202f% der F\u00e4lle Dronabinol (z.\u202fB. als Rezeptur oder Marinol\u00ae [AbbVie, IL, USA]), in 18\u202f% Cannabisbl\u00fcten, in 13\u202f% Sativex\u00ae (GW Pharma, Cambridge, UK), in 0,3\u202f% Nabilon (z.\u202fB. Canemes\u00ae [AOP Orphan Pharmaceuticals AG, Wien, \u00d6sterreich]) und in 4\u202f% (mit zunehmender Tendenz) Cannabisextrakt. Die Fallzahl von 6485\u00a0F\u00e4llen erlaubt bei Dronabinol bereits die Auswertung von Subgruppen hinsichtlich der therapeutischen Wirksamkeit. F\u00fcr Cannabis typische Nebenwirkungen, wie M\u00fcdigkeit, Schwindel, Schl\u00e4frigkeit, \u00dcbelkeit und Mundtrockenheit, traten bei der Verwendung aller Cannabisarzneimittel auf und sind bereits aus den Fachinformationen der cannabisbasierten Fertigarzneimittel bekannt. Potenziell schwerwiegende Nebenwirkungen wie Depression, Suizidgedanken, Wahnvorstellungen, Halluzinationen, Dissoziation und Sinnest\u00e4uschungen sind in jeweils mehr als einem von 1000 F\u00e4llen gemeldet worden.<\/jats:p><jats:p>Mit Cannabisbl\u00fcten behandelte Personen sind deutlich j\u00fcnger und weisen einen erheblich h\u00f6heren M\u00e4nneranteil auf. Sie werden h\u00e4ufiger haus\u00e4rztlich behandelt (Allgemeinmedizin, innere Medizin), weichen h\u00e4ufiger von den \u00fcblicherweise behandelten Diagnosen (Schmerz, Spastik und Anorexie\/Wasting) ab und verf\u00fcgen \u00fcber mehr Vorerfahrungen mit Cannabis. Das in der Begleiterhebung bestehende Underreporting betrifft diese Fallgruppe am st\u00e4rksten.<\/jats:p>","DOI":"10.1007\/s00103-021-03285-1","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T05:45:41Z","timestamp":1612935941000},"page":"368-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["3 Jahre Cannabis als Medizin\u00a0\u2013 Zwischenergebnisse der Cannabisbegleiterhebung","Three years of cannabis as medicine\u2014preliminary results of the survey accompanying the prescription of medical cannabis in Germany"],"prefix":"10.1007","volume":"64","author":[{"given":"Gabriele","family":"Schmidt-Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Cremer-Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"3285_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00103-019-02968-0","volume":"62","author":"G Schmidt-Wolf","year":"2019","unstructured":"Schmidt-Wolf\u00a0G, Cremer-Schaeffer\u00a0P (2019) Begleiterhebung zur Anwendung von Cannabisarzneimitteln in Deutschland \u2013 Zwischenauswertung. Bundesgesundheitsblatt 62:845. https:\/\/doi.org\/10.1007\/s00103-019-02968-0","journal-title":"Bundesgesundheitsblatt"},{"key":"3285_CR2","unstructured":"Verordnung \u00fcber die Begleiterhebung nach \u00a7 31 Absatz 6 des F\u00fcnften Buches Sozialgesetzbuch (Cannabis-Begleiterhebungs-Verordnung \u2013 CanBV) vom 23. M\u00e4rz 2017 (BGBl I S. 520)"},{"key":"3285_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00482-019-00399-z","volume":"33","author":"P Cremer-Schaeffer","year":"2019","unstructured":"Cremer-Schaeffer\u00a0P, Schmidt-Wolf\u00a0G, Broich\u00a0K (2019) Cannabisarzneimittel in der Schmerztherapie \u2013 Zwischenauswertung der Cannabisbegleiterhebung hinsichtlich der prim\u00e4r behandelten Symptomatik Schmerz. Schmerz 33:415. https:\/\/doi.org\/10.1007\/s00482-019-00399-z","journal-title":"Schmerz"},{"key":"3285_CR4","unstructured":"Sativex\u00ae (2015) Fachinformation https:\/\/www.fachinfo.de\/suche\/fi\/013156 Zugegriffen: 30. September 2020"},{"key":"3285_CR5","unstructured":"Canemes\u00ae (2019) Fachinformation. https:\/\/www.fachinfo.de\/suche\/fi\/021517 Zugegriffen: 30. September 2020"},{"key":"3285_CR6","unstructured":"Marinol\u00ae (2017) Prescribing Information (U.S.) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018651s029lbl.pdf Zugegriffen: 30. September 2020"},{"key":"3285_CR7","unstructured":"GKV GAmSi-Berichte: Monatliche Bruttoums\u00e4tze von Cannabinoid-haltigen Fertigarzneimitteln und Zubereitungen. https:\/\/www.gkv-gamsi.de\/media\/dokumente\/quartalsberichte\/2020\/q1_21\/Bundesbericht_GAmSi_202003_konsolidiert_Sonderbeilage_Cannabis.pdf. Zugegriffen: 30. Sept. 2020"},{"key":"3285_CR8","unstructured":"AWMF online (2017) Langfassung der Leitlinie \u201eADHS bei Kindern, Jugendlichen und Erwachsenen\u201c. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/028-045l_S3_ADHS_2018-06.pdf. Zugegriffen: 30. Sept. 2020"},{"key":"3285_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000883","author":"RL Page 2nd","year":"2020","unstructured":"Page\u00a0RL 2nd, Allen\u00a0LA, Kloner\u00a0RA, Carriker\u00a0CR, Martel\u00a0C, Morris\u00a0AA, Piano\u00a0MR, Rana\u00a0JS, Saucedo\u00a0JF, American Heart Association Clinical Pharmacology Committee, Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, Council on Lifestyle and Cardiometabolic Health, Council on Quality of Care and Outcomes Research (2020) Medical marijuana, recreational cannabis, and cardiovascular health: a scientific statement from the American Heart Association. Circulation. https:\/\/doi.org\/10.1161\/CIR.0000000000000883","journal-title":"Circulation"},{"issue":"1","key":"3285_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/bcp.14140","volume":"86","author":"G Crescioli","year":"2020","unstructured":"Crescioli\u00a0G, Lombardi\u00a0N, Bettiol\u00a0A, Menniti-Ippolito\u00a0F, Da Cas\u00a0R, Parrilli\u00a0M, Del Lungo\u00a0M, Gallo\u00a0E, Mugelli\u00a0A, Maggini\u00a0V, Firenzuoli\u00a0F, Vannacci\u00a0A (2020) Adverse events following cannabis for medical use in Tuscany: an analysis of the Italian Phytovigilance database. Br J Clin Pharmacol 86(1):106\u2013120. https:\/\/doi.org\/10.1111\/bcp.14140","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3285_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/npp.2017.209","volume":"43","author":"DL Boggs","year":"2018","unstructured":"Boggs\u00a0DL, Nguyen\u00a0JD, Morgenson\u00a0D, Taffe\u00a0MA, Ranganathan\u00a0M (2018) Clinical and preclinical evidence for functional interactions of Cannabidiol and \u22069-Tetrahydrocannabinol. Neuropsychopharmacology 43(1):142\u2013154. https:\/\/doi.org\/10.1038\/npp.2017.209","journal-title":"Neuropsychopharmacology"},{"key":"3285_CR12","unstructured":"IQWiG (2018) [A18\u201327] Extrakt aus Cannabis sativa (Spastik aufgrund von multipler Sklerose) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V (Ablauf Befristung). https:\/\/www.iqwig.de\/de\/projekte-ergebnisse\/projekte\/arzneimittelbewertung\/2018\/a18-27-extrakt-aus-cannabis-sativa-spastik-aufgrund-von-multipler-sklerose-nutzenbewertung-gemaess-35a-sgb-v-ablauf-befristung.9646.html. Zugegriffen: 30. Sept. 2020"},{"key":"3285_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/ane.13313","volume":"142","author":"D Vecchio","year":"2020","unstructured":"Vecchio\u00a0D, Varrasi\u00a0C, Virgilio\u00a0E, Spagarino\u00a0A, Naldi\u00a0P, Cantello\u00a0R (2020) Cannabinoids in multiple sclerosis: a neurophysiological analysis. Acta Neurol Scand 142:333\u2013338. https:\/\/doi.org\/10.1111\/ane.13313","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"3285_CR14","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","volume":"31","author":"P Grimison","year":"2020","unstructured":"Grimison\u00a0P, Mersiades\u00a0A, Kirby\u00a0A, Lintzeris\u00a0N, Morton\u00a0R, Haber\u00a0P, Olver\u00a0I, Walsh\u00a0A, McGregor\u00a0I, Cheung\u00a0Y, Tognela\u00a0A, Hahn\u00a0C, Briscoe\u00a0K, Aghmesheh\u00a0M, Fox\u00a0P, Abdi\u00a0E, Clarke\u00a0S, Della-Fiorentina\u00a0S, Shannon\u00a0J, Gedye\u00a0C, Begbie\u00a0S, Simes\u00a0J, Stockler\u00a0M (2020) Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a\u00a0randomised, placebo-controlled, phase II crossover trial. Ann Oncol 31(11):1553\u20131560. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.020","journal-title":"Ann Oncol"},{"issue":"4","key":"3285_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/ana.25864","volume":"88","author":"M Peball","year":"2020","unstructured":"Peball\u00a0M, Krismer\u00a0F, Knaus\u00a0HG, Djamshidian\u00a0A, Werkmann\u00a0M, Carbone\u00a0F, Ellmerer\u00a0P, Heim\u00a0B, Marini\u00a0K, Valent\u00a0D, Goebel\u00a0G, Ulmer\u00a0H, Stockner\u00a0H, Wenning\u00a0GK, Stolz\u00a0R, Krejcy\u00a0K, Poewe\u00a0W, Seppi\u00a0K (2020) Collaborators of the parkinson\u2019s disease working group Innsbruck. Non-motor symptoms in parkinson\u2019s disease are reduced by Nabilone. Ann Neurol 88(4):712\u2013722. https:\/\/doi.org\/10.1002\/ana.25864","journal-title":"Ann Neurol"},{"key":"3285_CR16","doi-asserted-by":"publisher","first-page":"E206","DOI":"10.1503\/cmaj.191097","volume":"192","author":"T Antoniou","year":"2020","unstructured":"Antoniou\u00a0T, Bodkin\u00a0J, Ho\u00a0J (2020) Drug interactions with cannabinoids. Can Med Assoc J 192:E206. https:\/\/doi.org\/10.1503\/cmaj.191097","journal-title":"Can. Med. Assoc. J."},{"key":"3285_CR17","volume-title":"Cannabis: Potenzial und Risiko: Eine wissenschaftliche Bestandsaufnahme","year":"2019","unstructured":"Hoch\u00a0E, Friemel\u00a0CM, Schneider\u00a0M (Hrsg) (2019) Cannabis: Potenzial und Risiko: Eine wissenschaftliche Bestandsaufnahme. Springer, Berlin, Heidelberg"},{"key":"3285_CR18","volume-title":"The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017","unstructured":"National Academies of Sciences, Engineering, and Medicine (2017) The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies Press, Washington, DC"},{"issue":"5","key":"3285_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00482-019-0373-3","volume":"33","author":"W H\u00e4user","year":"2019","unstructured":"H\u00e4user\u00a0W, Welsch\u00a0P, Klose\u00a0P, Radbruch\u00a0L, Fitzcharles\u00a0MA (2019) Efficacy, tolerability and safety of cannabis-based medicines for cancer pain: a systematic review with meta-analysis of randomised controlled trials. Schmerz 33(5):424\u2013436. https:\/\/doi.org\/10.1007\/s00482-019-0373-3","journal-title":"Schmerz"},{"issue":"12","key":"3285_CR20","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1055\/a-1008-7427","volume":"87","author":"E Hoch","year":"2019","unstructured":"Hoch\u00a0E, Preuss\u00a0UW (2019) Cannabis, Cannabinoide und Cannabiskonsumst\u00f6rungen. Fortschr Neurol Psychiatr 87(12):714\u2013728. https:\/\/doi.org\/10.1055\/a-1008-7427","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"5","key":"3285_CR21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00482-019-00409-0","volume":"33","author":"W H\u00e4user","year":"2019","unstructured":"H\u00e4user\u00a0W, Hoch\u00a0E, Petzke\u00a0F, Thomasius\u00a0R, Radbruch\u00a0L, Batra\u00a0A, Sommer\u00a0C, Havemann-Reinecke\u00a0U (2019) Medizinalcannabis und cannabisbasierte Arzneimittel: ein Appell an \u00c4rzte, Journalisten, Krankenkassen und Politiker f\u00fcr einen verantwortungsvollen Umgang. Schmerz 33(5):466\u2013470. https:\/\/doi.org\/10.1007\/s00482-019-00409-0","journal-title":"Schmerz"},{"issue":"5","key":"3285_CR22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00482-019-00410-7","volume":"33","author":"O Tolmein","year":"2019","unstructured":"Tolmein\u00a0O (2019) Medizinische Versorgung mit Cannabis \u2013 die Rechtslage kl\u00e4rt sich. Schmerz 33(5):443\u2013448. https:\/\/doi.org\/10.1007\/s00482-019-00410-7","journal-title":"Schmerz"},{"issue":"5","key":"3285_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s00482-019-00408-1","volume":"33","author":"C Wendelmuth","year":"2019","unstructured":"Wendelmuth\u00a0C, Wirz\u00a0S, Torontali\u00a0M, Gastmeier\u00a0A, Gastmeier\u00a0K (2019) Dronabinol bei geriatrischen Schmerz- und Palliativpatienten : Eine retrospektive Auswertung der ambulanten kassen\u00e4rztlichen Therapie. Schmerz 33(5):384\u2013391. https:\/\/doi.org\/10.1007\/s00482-019-00408-1","journal-title":"Schmerz"},{"issue":"5","key":"3285_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00482-019-00406-3","volume":"33","author":"K Gastmeier","year":"2019","unstructured":"Gastmeier\u00a0K (2019) Einsatz von Cannabisarzneimitteln in der Schmerz- und Palliativmedizin : Gemeinsame Online-Umfrage des Berufsverbands der \u00c4rzte und Psychotherapeuten in der Schmerz- und Palliativmedizin in Deutschland e.\u202fV.(BVSD), der Deutschen Schmerzgesellschaft e.\u202fV. und der Deutschen Gesellschaft f\u00fcr Schmerzmedizin e.\u202fV. (DGS). Schmerz 33(5):408\u2013414. https:\/\/doi.org\/10.1007\/s00482-019-00406-3","journal-title":"Schmerz"},{"issue":"5","key":"3285_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00482-019-00402-7","volume":"33","author":"C Wendelmuth","year":"2019","unstructured":"Wendelmuth\u00a0C, Gastmeier\u00a0K (2019) Hochdosisdronabinoltherapie vs. Medizinalcannabisbl\u00fcten. Schmerz 33(5):392\u2013398. https:\/\/doi.org\/10.1007\/s00482-019-00402-7","journal-title":"Schmerz"},{"issue":"5","key":"3285_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00482-019-00407-2","volume":"33","author":"F Petzke","year":"2019","unstructured":"Petzke\u00a0F, Karst\u00a0M, Gastmeier\u00a0K, Radbruch\u00a0L, Steffen\u00a0E, H\u00e4user\u00a0W, Ad-hoc-Kommission der Deutschen Schmerzgesellschaft \u201eCannabis in der Medizin\u201c (2019) Ein Positionspapier zu medizinischem Cannabis und cannabisbasierten Medikamenten in der Schmerzmedizin. Schmerz 33(5):449\u2013465. https:\/\/doi.org\/10.1007\/s00482-019-00407-2","journal-title":"Schmerz"},{"issue":"5","key":"3285_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00482-019-00397-1","volume":"33","author":"M Heidbreder","year":"2019","unstructured":"Heidbreder\u00a0M, van Treeck\u00a0B (2019) Cannabispr\u00e4parate f\u00fcr die Therapie chronischerSchmerzen : Problemfelder bei medizinischen Begutachtungen aus der Erfahrung des MDK Nord. Schmerz 33(5):437\u2013442. https:\/\/doi.org\/10.1007\/s00482-019-00397-1","journal-title":"Schmerz"},{"issue":"5","key":"3285_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00482-019-0383-1","volume":"33","author":"P Bialas","year":"2019","unstructured":"Bialas\u00a0P, Drescher\u00a0B, Gottschling\u00a0S, Juckenh\u00f6fel\u00a0S, Konietzke\u00a0D, Kuntz\u00a0W, K\u00fchne-Adler\u00a0I, Merl-Ripplinger\u00a0H, Preisegger\u00a0D, Schneider\u00a0K, Strau\u00df\u00a0M, Welsch\u00a0P, H\u00e4user\u00a0W (2019) Cannabispr\u00e4parate bei chronischen Schmerzen: Indikationen, Pr\u00e4parateauswahl, Wirksamkeit und Sicherheit: Erfahrungen der saarl\u00e4ndischen Schmerztherapeuten. Schmerz 33(5):399\u2013406. https:\/\/doi.org\/10.1007\/s00482-019-0383-1","journal-title":"Schmerz"},{"key":"3285_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2147\/JPR.S240011","volume":"13","author":"MA \u00dcberall","year":"2020","unstructured":"\u00dcberall\u00a0MA (2020) A review of scientific evidence for THC:CBD Oromucosal spray (Nabiximols) in the management of chronic pain. J\u00a0Pain Res 13:399\u2013410. https:\/\/doi.org\/10.2147\/JPR.S240011","journal-title":"J Pain Res"},{"key":"3285_CR30","volume-title":"Am Puls der Versorgung \u2013 was passiert da gerade?","author":"U Marschall","year":"2020","unstructured":"Marschall\u00a0U (2020) Am Puls der Versorgung \u2013 was passiert da gerade? Deutscher Schmerz- und Palliativtag, 21. Juli 2020 (Vortrag)"},{"key":"3285_CR31","unstructured":"GKV Spitzenverband (2020) Per Mail angefragte Informationen zur Geltendmachung der Abrechnungsziffern 01460, 01461 und 01626"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-021-03285-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00103-021-03285-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-021-03285-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T12:52:37Z","timestamp":1614862357000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00103-021-03285-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["3285"],"URL":"https:\/\/doi.org\/10.1007\/s00103-021-03285-1","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"assertion":[{"value":"12 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Schmidt-Wolf und P.\u00a0Cremer-Schaeffer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Die Erfassung der Patientendaten erfolgt anonym. Die Information der Patientinnen\/Patienten ist in der Cannabis-Begleiterhebungsverordnung in \u00a7 3 geregelt [].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}